| Firm | Analyst | Phone | Type | Rating | |
|---|---|---|---|---|---|
|
Baird Equity Research
|
Brian Skorney | ||||
|
Bank of America Merrill Lynch
|
Jason M. Gerberry | ||||
|
Bloom Burton
|
David Martin | ||||
|
Cantor Fitzgerald
|
Josh Schimmer | ||||
|
Chardan
|
Rudy Li | ||||
|
Cowen
|
Joseph Thome | ||||
|
Deutsche Bank
|
David Hoang | ||||
|
Evercore ISI
|
Cory Kasimov | ||||
|
Goldman Sachs
|
Paul Choi | ||||
|
Guggenheim Securities
|
Yatin Suneja | ||||
|
H.C. Wainwright
|
Douglas Tsao | ||||
|
Jefferies
|
Andrew Tsai | ||||
|
J.P. Morgan
|
Tessa T. Romero | ||||
|
Leerink
|
Marc Goodman | ||||
|
Needham
|
Serge Belanger | ||||
|
RBC Capital Markets
|
Brian Abrahams | ||||
|
Stifel Nicolaus
|
Paul Matteis | ||||
|
Wedbush
|
Laura Chico | ||||
|
Wells Fargo
|
Benjamin Burnett | ||||
|
William Blair
|
Myles Minter |
Xenon Pharmaceuticals Inc. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Xenon Pharmaceuticals Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Xenon Pharmaceuticals Inc. or its management. Xenon Pharmaceuticals Inc. does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.